Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.

Abstract

: We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.

• Authors: Antonella Castagna, Stefano Rusconi, Roberto Gulminetti, Stefano Bonora, Giovanni Mazzola, Maria E Quiros-Roldan, Giuseppe V De Socio, Nicoletta Ladisa, Sinibaldo Carosella, Annamaria Cattelan, Simona Di Giambenedetto, Maurizio Mena, Andrea Poli, Laura Galli, Agostino Riva, DAU Study Group
• Journal: AIDS (London, England) (AIDS) Vol. 33 Issue 7 Pg. 1256-1260 (06 01 2019) ISSN: 1473-5571 [Electronic] England
• PMID: 30870194 (Publication Type: Letter, Research Support, Non-U.S. Gov't)

Chemical References

• HIV Integrase Inhibitors
• Heterocyclic Compounds, 3-Ring
• Oxazines
• Piperazines
• Pyridones
• RNA, Viral
• Atazanavir Sulfate
• dolutegravir

Topics

• Antiretroviral Therapy, Highly Active
• Atazanavir Sulfate (therapeutic use)
• CD4 Lymphocyte Count
• Drug Substitution
• Drug Therapy, Combination
• Female
• HIV Infections (drug therapy)
• HIV Integrase Inhibitors (therapeutic use)
• HIV-1 (drug effects)
• Heterocyclic Compounds, 3-Ring (therapeutic use)
• Humans
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Oxazines
• Piperazines
• Pyridones
• RNA, Viral (blood)
• Treatment Outcome
• Viral Load